Aleniglipron: Research & Studies

Research Overview#

Aleniglipron was evaluated in the Phase 2b ACCESS program announced in December 2025. The 120 mg dose achieved 11.3% placebo-adjusted weight loss at 36 weeks, and the exploratory 240 mg dose showed up to 15.3%. Phase 3 is planned for mid-2026.

ACCESS Phase 2b Results#

The core study enrolled 230 adults randomized to aleniglipron (45, 90, or 120 mg after titration) or placebo for 36 weeks. At 120 mg, 86% achieved at least 5% weight loss and 70% achieved at least 10%.

Evidence Quality#

Research Evidence Context#

Aleniglipron belongs to the Metabolic category of research peptides. The research evidence for Aleniglipron spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for Aleniglipron:

Phase 2b ACCESS Study of Aleniglipron in Adults with Obesity or Overweight#

Authors: Structure Therapeutics investigators (2025) — Press release (Structure Therapeutics)

Phase 2b study enrolling 230 adults with obesity or overweight with comorbidities. Participants titrated from 5 mg to 45, 90, or 120 mg daily for 36 weeks. The 120 mg dose achieved 11.3% placebo-adjusted weight loss.

Key Findings:

• 11.3% placebo-adjusted weight loss at 120 mg at 36 weeks
• 86% of 120 mg participants achieved 5% or more weight loss
• 70% of 120 mg participants achieved 10% or more weight loss
• Discontinuation rate of 7.7-13.3% across dose groups (mean 10.4%)

Limitations: Press release data only; full peer-reviewed publication pending; 36-week duration; no active comparator arm

ACCESS II Exploratory Study of Higher-Dose Aleniglipron#

Authors: Structure Therapeutics investigators (2025) — Press release (Structure Therapeutics)

Exploratory study evaluating 240 mg dose showing greater weight loss than the core ACCESS study.

Key Findings:

• Up to 15.3% placebo-adjusted weight loss at 240 mg at 36 weeks
• Supports dose-response relationship for aleniglipron

Limitations: Exploratory study; smaller sample size; press release data only

Evidence Quality Assessment#

The overall evidence level for Aleniglipron is classified as moderate. There is meaningful clinical evidence from Phase 2 or similar trials, though larger confirmatory studies may be needed.

Research Gaps and Future Directions#

The following gaps in the current evidence base for Aleniglipron have been identified:

• No peer-reviewed full publication of Phase 2b results
• No cardiovascular outcomes data
• No head-to-head comparison with orforglipron
• Optimal Phase 3 dose selection to be determined
• No data in type 2 diabetes populations

Addressing these research gaps will be important for establishing a more complete understanding of Aleniglipron's therapeutic potential and safety profile.

Related Reading#

• Aleniglipron overview and research guide
• Aleniglipron dosing protocols
• Aleniglipron molecular structure